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Background: Inflow of tumor cells to circulation is an essential step for metastasis of
primary tumors. To know its state may contribute to therapeutic strategy. However,
methodology to detect lung carcinoma cells floating in peripheral blood has not been
established. Pulmonary surfactant protein (SP)-A, SP-C and Clara cells-10 kd protein
(CC10) are specific to the lung and often expressed in primary lung carcinomas. We
evaluated the worth of these gene expressions for the detection of carcinoma cells
in peripheral blood.
Methods: The expressions in 5ml of venous blood were tested by RT-PCR. Ninety-
nine patients with non-small cell lung carcinoma (NSCLC) and 17 with small cell lung
carcinoma (SCLC) were compared to 13 with secondary lung tumor, 48 with non-
malignant respiratory diseases and 19 healthy volunteers.
Results: The mRNA expressions of SP-A and SP-C were completely specific to NSCLC
when compared to SCLC and secondary lung tumors. All of the healthy volunteers
and patients with non-malignant respiratory diseases showed negative for these
mRNA expressions, except for one sample. The positive rate of SP-A, SP-C and CC10
mRNA in patients with NSCLC was 33.3%, 14.1%, 3.3%, respectively. The rates of SP-A
and SP-C mRNA were higher than that (11.1%) in CEA mRNA. The increased positive
rate of mRNA of SP-A and SP-C was significantly dependent on the clinical stage and
the existence of distant metastasis.Elsevier Ltd. All rights reserved.
611 2111; fax: +81 11 613 1543.
jp (H. Takahashi).
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Detection of SP-A and SP-D mRNA in circulation 1165Conclusion: These results demonstrate that the detection of mRNA of SP-A and SP-C
would give clinicians valuable information suggesting the presence of blood-floating
carcinoma cells as a step toward metastasis.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Primary lung carcinoma is a disease with a very
poor prognosis. Even if absolute resection is
successfully performed, only 60–70% of patients
with stage I primary lung carcinoma according to
the TNM classification have survived for 5 years.1,2
This poor prognosis may be caused by late diagnosis
which was obtained after the occurrence of
micrometastasis. Although the entry of tumor cells
from the primary site into the peripheral blood
plays an important step in the multi-step process of
metastasis, the detection of tumor cells in periph-
eral blood using the cytological method does not
appear to be practical because of its low sensitivity.
Using several markers, including cytokeratin (CK)
and carcinoembryonic antigen (CEA), reverse tran-
scriptase-polymerase chain reaction (RT-PCR) has
recently been used to detect circulating lung
carcinoma cells in peripheral blood.3 However,
employing these markers can sometimes cause
serious problems; mixing of the skin epithelial cells
at the time of sample extraction,4,5 and the
existence of pseudogenes.6,7 Furthermore, since
these markers are not specific for the lung, they do
not appear to be suitable for distinguishing primary
lung carcinomas from metastatic neoplasms of the
lung. In the search for a candidate marker which
could overcome these problems, we focused our
study on surfactant protein (SP)-A, SP-C and Clara
cell 10 kd protein (CC10). SP-A is a marker for both
alveolar type II cells and Clara cells in peripheral
lung tissues, while SP-C and CC10 provides a
particularly high specificity to alveolar type II cells
and Clara cells, respectively.
By using anti-SP-A monoclonal antibodies, we
have previously demonstrated that SP-A was posi-
tively detected in 50% of primary lung adenocarci-
noma tissues but was not present at all in tissues of
metastatic lung tumor.8 Nomori and colleagues9
also reported that the expression rates of SP-A and
CC10 in tissues of primary lung adenocarcinoma
were 65.3% and 10.2%, respectively. Several cell
lines of lung carcinoma expressed mRNA for SP-A
and SP-C.10,11 In pleural effusions from patients
with primary lung adenocarcinoma, RT-PCR for SP-A
mRNA showed a sensitivity of 83% and a specificity
of 100%, suggesting that SP-A could be a worthy
indicator for differential diagnosis.12The purpose of this study was to examine whether
mRNAs of the lung specific proteins are detected in
peripheral blood of patients with lung carcinomas
and whether the detection rates are associated with
clinical stage and distant metastasis.Materials and methods
Patients
We enrolled 116 patients with lung carcinomas who
visited Sapporo Medical University Hospital; 78 with
adenocarcinomas, 18 with squamous cell carcino-
mas, 2 with adenosquamous carcinomas, 1 with
large cell carcinoma and 17 with small| cell lung
carcinomas (SCLC). The 116 patients with lung
carcinoma were classified according to the TNM
classification.13 As controls, the 48 patients with
non-malignant respiratory diseases and from the 19
healthy volunteers were examined. The 13 meta-
static tumor patients were also examined. Inter-
stitial pulmonary fibrosis (IPF) and lung carcinoma
are known to be frequently associated. The chest-
X-ray findings of IPF often show a homogenous
increase in density, which makes an early diagnosis
of lung carcinoma difficult. We therefore excluded
IPF cases from the control samples in our study.Mononuclear cell Isolation and RNA
extraction
This study was approved by the Sapporo Medical
University Ethics Committee, and informed consent
was obtained from each subject. The samples from
patients with lung carcinoma were extracted
before medical treatment. We collected peripheral
venous blood samples (5ml) in EDTA tubes. Mono-
nuclear cells from peripheral blood samples were
isolated using Ficoll gradient centrifugation.
Briefly, blood samples were centrifuged to separate
plasma. The plasma was stored at 30 1C until SP-A
measurement. The remainder was diluted with PBS
and then layered on 5ml of Ficoll gradient solution.
The gradient was centrifuged at 350g for 30min.
Total RNA extraction was performed by using Trizol
reagent (Life Technologies, Inc. Rockville, MD)
according to the manufacturer’s instructions.
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O. Yamamoto et al.1166Reverse transcriptase (RT)-polymerase chain
reaction (PCR)
RT reaction was prepared in a final volume of 20 ml
containing 5 mg RNA, 1 ml of Oligo (dT)12–18 (500 mg/
ml), and 1 ml of SuperScriptTM RNase H-reverse
transcriptase (Life Technologies, Rockville, MD). RT
reaction was incubated at 42 1C for 50min followed
by a 15min-incubation at 70 1C. Integrity of RNA
and adequate cDNA synthesis was confirmed by
determining the presence of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) mRNA in the
sample. The PCR amplification conditions were 30 s
at 95 1C, 30 s at 55 1C, and 1min at 72 1C for 37
cycles. SP-A, SP-C, CC10, CEA and GAPDH-specific
oligonucleotide primers were synthesized accord-
ing to the published sequence information. These
primer sequences and the PCR product fragments
are shown in Table 1. One ml from the cDNA pool
was used for the first PCR amplification in a final
volume of 25 ml. The conditions were as follows; SP-
A: 30 s at 95 1C, 30 s at 55 1C, and 1min at 72 1C for
37 cycles; SP-C and CC10: 30 s at 95 1C, 30 s at 57 1C
and 1min at 72 1C for 30 cycles; CEA: 30 s at 95 1C,
30 s at 57 1C, and 1min at 72 1C for 37 cycles. Then,
1 ml from the first PCR product (25 ml) was used for
the second PCR amplification under the same
conditions as in the first PCR amplification. We
used filter tips in all experiments, and used Ready
to GoTM PCR Beads (Amersham Biosciences, Piscat-Table 1 Sequences of oligonucleotide primers for the ne
GAPDH, each product size and reference.
Trascripts Oligoneculeotide Primer
SP-A First primer Sense 50GTGCGAAGTGAAGGACGT
Antisense 50CAGTCGGGAGTACAGGCA
Nested primer Sense 50AGCTCATCTAGATGAGGAG
Antisense 50CGGTACCAGTTGGTGTAG
SP-C First primer Sense 50AAAGAGGTCCTGATGGAG
Antisense 50TA GATGTAGTAGAGCGGC
Nested primer Sense 50AACGCCTTCTTATCGTGGT
Antisense 50 GTGAGAGCCTCAAGACT
CC10 First primer Sense 50ATGAAACTCGCTGTCACC
Antisense 50ATTACACAGTGAGCTTTGG
Nested primer Sense 50GTCACACTGGCTCTCTGC
Antisense 50TGATGCTTTCTCTGGGCT
CEA First primer Sense 50AGGAGGACAGAGCAGACA
Antisense 50 TGGCAGGAGAGGTTCAG
Nested primer Sense 50CCATGGAGTCTCCCTGT 3
Antisense 50GTAGCTTGTGTCATTTC 3
GAPDH Sense 50ATCTGGCACCACACCTTCT
Antisense 50CGTCATACTCCTGCTTGCTaway, NJ). RNA from the normal lung tissue was
used as positive controls for the PCR of SP-A, SP-C
and CC10, but not for the PCR for CEA, for which
RNA from lung adenocarcinoma cell line A549
(Japanese Collection of Research Bioresources
Bank) was used. Samples were electrophoresed on
2% agarose gels and visualized by ethidium bromide
staining.
Sequencing
To identify PCR products obtained for SP-A, SP-C,
CC10 and CEA primers, the samples were purified
with GFXTM PCR DNA and a Gel Band Purification kit
(Amersham Pharmacia Biotech) following 1.5%
agarose gel electrophoresis. They were then sub-
cloned into pCR 2.1 vector with a TA cloning kit
(Invitrogen, Carlsbad, CA). The nucleotide se-
quences of the clones were determined using an
ABI Genetic analyzer PRIM 310 and an AmpliCycle
sequencing kit (Perkin-Elmer, Foster City, CA).
Sensitivity of RT-PCR
104,103,102,10, and one of the lung adenocarcino-
mas cells, 196TC cells, which have been isolated
from pleural effusion of a patient with lung
adenocarcinoma and had been demonstrated to
express mRNAs for these proteins, were mixed with
5 106 mononuclear cells from normal donorsted RT-PCR amplification of SP-A, SP-C, CC10, CEA and
Product size (bp) References
TTGT30 673 White et al.35
GTTC30
CTCCA30 338
TTTACAGG30
AGC3 456 Glasser et al.36
ACCT30
G30 313
GG30
CT30 273 Sing et al.37
GCTAT30
TG30 205
TT3
GC30 806 Schrewe et al.38
ATT3
0 641
0
ACAATGAGCTGCG30 226 Tokunaga et al.39
GATCCACATCTGC30
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Figure 1 Sensitivity of the RT-PCR assay for SP-A, SP-C,
CC10, and CEA mRNA. 196TC cells (104,103,102,10, and 1
lung adenocarcinoma) which are known to express mRNA
for these proteins, were mixed with 5 106 mononuclear
cells from normal donor peripheral blood. Each prepara-
tion containing various number of cancer cells were
tested for mRNA by nested RT-PCR. RT-PCR was able to
detect mRNA for SP-A, SP-C, CC10 and CEA, even when a
single 196TC lung adenocarcinoma cell was mixed with
5 106 normal mononuclear cells.
Detection of SP-A and SP-D mRNA in circulation 1167peripheral blood. Each preparation containing
various numbers of cancer cells was tested for
mRNA by RT-PCR according to above-mentioned
method.
Assay for serum SP-A and CEA
The plasma samples were assayed for SP-A with a
sandwich-type enzyme-linked immunoassay using
an SP-A test F kit (International Reagents Co.,
Kobe, Japan). Serum CEA levels were measured by
electrochemiluminescence immunoassay with an
Elecsys CEA II kit (Roch Diagnostics, Mannheim,
Germany).
Statistical analysis
The correlation between clinicopathlogical para-
meters and RT-PCR assays was evaluated by means
of Unpaired t-test and Fisher’s exact probability
test. Continuous variables with non-parametric
distribution were compared by means of the
Mann–Whitney U test.Results
Sequencing and sensitivity of RT-PCR in
detecting mRNAs for SP-A, SP-C, CC10 and
CEA
The sequence analysis performed on circulating
cells in patients with lung carcinoma confirmed
that each of the amplified PCR products was cDNA
for SP-A, SP-C, CC10 and CEA. RT-PCR was able to
detect mRNAs for SP-A, SP-C, CC10 and CEA, even
when only one 196TC lung adenocarcinoma cell was
mixed with 5 106 normal mononuclear cells
(Fig. 1).
Specific expression of each molecular
marker in various diseases
RNA integrity was confirmed in all clinical samples
by positive GAPDH RT-PCR signal. The patients were
divided into four disease groups: non-neoplastic
respiratory disease, metastatic lung tumor, SCLC
and NSCLC. The NSCLC consisted of 78 patients with
adenocarcinoma, 18 patients with squamous cell
carcinoma, 2 patients with adenosquamous cell
carcinoma and 1 large cell carcinoma. The mean
age, gender, smoking situation and the results of
mRNA expressions are shown in Table 2 and those of
NSCLC are seen in Table 3. The electropherogram of
PCR products in the representative cases are alsoshown in Fig. 2. All 19 samples from healthy
volunteers were negative for SP-A, SP-C, CC10
and CEA mRNA expression. When positive rates of
SP-A mRNA were compared among the disease
groups, substantial differences were observed.
Thirty-three of the 99 patients (33.3%) with NSCLC
showed positive. Seventy-seven of 78 patients in
the other disease groups showed negative for SP-A;
the exception was the case of severe lung abscess.
Although expression for SP-C mRNA was exclusive in
NSCLC patients, its positive rate (14 of 99 patients,
14.1%) was lower than that of SP-A mRNA. CC10
mRNA was expressed in one patient (7.7%) with
metastatic lung carcinoma and 3 patients (3.3%)
with NSCLC. CEA mRNA was expressed in 2 patients
(15.4%) with metastatic lung carcinoma, 3 patients
(17.6%) with small cell lung carcinoma, and 11
patients (11.1%) with NSCLC. These results show
that CEA exhibits very little specificity to lung
carcinomas and histological types.
When the positive rates of the four gene markers
in the 99 patients with NSCLC were compared, SP-A
showed the highest rate (33.3%), while the positive
rates of SP-C, CC10 and CEA were lower (14.1%,
3.3%, 11.1%, respectively). Of the 17 patients with
SCLC, none expressed mRNA of SP-A, SP-C or CC10,
while three expressed CEA mRNA. None of the 13
metastatic lung carcinomas showed positive mRNA
expression of SP-A or SP-C, while 1 patient was
CC10 positive (7.7%) and 2 patients were CEA
positive (15.4%). Of the 48 patients with non-
malignant respiratory diseases, none expressed any
types of mRNA except for the lung abscess patient.
Since the results, as shown in the Table 2,
demonstrate that the clinical implication of the
ARTICLE IN PRESS
Table 2 Expression of mRNAs in healthy volunteers and patients with various respiratory diseases.
Total Mean
age7SD
Male:female Smoking The number of
positive cases
C:F:N SP-A SP-C CC10 CEA
Healthy volunteers 19 34.279.5 12:7 6:1:2 0 0 0 0
Non-neoplastic respiratory diseasesy 48 57.5715.2 22:26 20:6:22 1 0 0 0
Secondary lung tumorz 13 66.1710.7 5:8 5:3:5 0 0 1 2
Small cell lung carcinomas 17 64.477.7 12:5 10:5:2 0 0 0 3
Non-small cell lung carcinomas 99 63.8710.1 71:28 48:22:29 33 14 3 11
C:F:N; the number of current: former: never smoking.
yInclude of bronchial asthma (n ¼ 6), pulmonary tuberculosis (n ¼ 6), pulmonary acute pneumonia (n ¼ 5), alveolar
proteinosis (n ¼ 5), bronchiolitis obliterans organizing pneumonia (n ¼ 4), pulmonary emphysema (n ¼ 3), sarcoidosis (n ¼ 3),
atypical mycobacterium (n ¼ 2), lymphocytic interstitial pneumonia (n ¼ 1), lung abscess (n ¼ 1), allergic bronchopulmonary
aspergillosis (n ¼ 1), eosinophilic pneumonia (n ¼ 1), middle lobe syndrome (n ¼ 1), lymphangioleiomyomatosis (n ¼ 1),
pulmonary alveolar microlithiasis (n ¼ 1), pneumoconiosis (n ¼ 1), old tuberculosis (n ¼ 1), aspergiloma (n ¼ 1), bronchiectasis
(n ¼ 1), empyema (n ¼ 1), lymph node tuberculosis (n ¼ 1), hamartoma (n ¼ 1).
zInclude of breast cancer (n ¼ 4), colon carcinoma (n ¼ 3), esophageal carcinoma (n ¼ 1), laryngeal carcinoma (n ¼ 1), renal
pelvic carcinoma (n ¼ 1), renal cell carcinoma (n ¼ 1), thyroid carcinoma (n ¼ 1), lingual carcinoma (n ¼ 1).
Table 3 Relation between mRNA expression and NSCLC patients’ characteristics.
No. of mRNA positive cases. (% of total)
Total SP-A SP-C CC10 CEA
Age
Mean age7SD63.8710.1
PCR negative 64.4710.4 63.3710.0 63.5710.0 64.0710.0
PCR positive 62.679.5 67.0710.2 73.776.5 62.5710.9
P ¼ 0.4000 P ¼ 0.1937 P ¼ 0.0856 P ¼ 0.6279
Gender
Male 71 26 (36.6%) 8 (11.2%) 2 (2.8%) 10 (14.1%)
Female 28 7 (25.0%) 6 (21.4%) 1 (3.6%) 1 (3.6%)
P ¼ 0.3463 P ¼ 0.2105 P40.9999 P ¼ 0.1725
Histological types
Adenocarcinoma 78 26 (33.3) 9 (11.5) 2 (2.6)
Squamous cell carcinoma 18 6 (33.3) 5 (27.8) 1 (5.5)
Adenosquamous cell carcinoma 2 1 (50.0) 0 (0.0) 0 (0.0)
Large cell carcinoma 1 0 (0.0) 0 (0.0) 0 (0.0)
P ¼ 0.8614 P ¼ 0.2974 P ¼ 0.9096 P ¼ 03939
Tobacco smoking
Never 29 10 (34.9%) 5 (17.2%) 1 (3.4%) 3 (10.3%)
Former 22 7 (24.1%) 3 (13.6%) 0 (0%) 1 (4.5%)
Current 48 16 (33.3%) 6 (12.5%) 2 (4.2%) 7 (14.6%)
P ¼ 0.9802 P ¼ 0.8434 P ¼ 0.6326 P ¼ 0.4576
P value by w2 test.
O. Yamamoto et al.1168gene markers was limited to patients with NSCLC,
we analyzed in detail whether the expressions of
mRNAs were influenced by age, gender, histologicaltypes of NSCLC and tobacco smoking. As shown in
Table 3, mRNA expressions were not influenced by
each characteristic.
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Table 4 Expression of mRNAs in NSCLC according to TNM
Total No. of mRNA positive ca
SP-A SP
TNM classification
I 35 8 (22.3) 2
II 6 0 (0.0) 1
III 21 8 (38.0) 2
IV 37 17 (45.9) 9
Total 99 33 (33.3) 14
P ¼ 0.0242 P
T factor
T1 29 6 (20.7) 2
T2 35 12 (34.3) 5
T3 3 1 (33.3) 0
T4 32 14 (43.8) 7
P ¼ 0.0610 P
N factor
NO 52 16 (30.8) 7
N1 10 3 (30.0) 1
N2 27 10 (37.0) 4
N3 10 4 (40.0) 2
P ¼ 0.4919 P
M factor
M0 62 16 (25.8) 5
M1 37 17 (45.9) 9
P ¼ 0.0407 P
P value by Mann–Whitney U test.
Figure 2 mRNA expression of SP-A, SP-C, CC10, CEA and
GAPDH in the peripheral blood from clinical subjects. The
cDNA segments with the following expected sizes: SP-A,
338 bp; SP-C, 313 bp; CC10, 205 bp; CEA, 641 bp were
amplified by RT-PCR using each primer. Lane 1, healthy
volunteer; Lanes 2 and 3, acute pneumonia; Lane 4,
metastatic lung tumor of renal cell carcinoma; Lane5,
metastatic lung tumor of colon carcinoma; Lanes 6–10,
primary lung adenocarcinoma; Lanes 11 and 12, primary
lung squamous cell carcinomas; Lane M, DNA molecular
weight markers; Lane N, water negative control; Lane P,
positive control.
Detection of SP-A and SP-D mRNA in circulation 1169Correlation of mRNA expression with clinical
stage in patients with NSCLC
We analyzed the relationship between the clinical
stage and mRNA positivity in NSCLC. The clinical
stage was classified from I–IV by the TNM system.
The results are shown in Table 4. In the patients
with metastasis (stage IV), the positive rate of
expression for each mRNA was highest in SP-A
(45.9%), followed by SP-C (24.3%), CEA (18.9%), and
CC10 (2.7%). It should be pointed out that mRNA
expressions of these proteins were confirmed in
patients without metastasis. Of particular note, the
positive rate of SP-A mRNA was unexpectedly high
(25.8%) in patients without metastasis, at stages I,
II and III.
The difference in the positive rate was analyzed
between the groups with and without metastasis.
The positive rates of SP-A and SP-C mRNAs in the
group with metastasis were significantly higher
than those in the group without metastasis
(P ¼ 0.0407 and 0.0254, respectively), while theclassification.
ses (% of total)
-C CC10 CEA
(5.7) 0 (0.0) 2 (5.7)
(16.7) 0 (0.0) 1 (16.7)
(9.5) 2 (9.5) 1 (4.8)
(24.3) 1 (2.7) 7 (18.9)
(14.1) 3 (3.3) 11 (11.1)
¼ 0.0275 P ¼ 0.4499 P ¼ 0.0911
(6.9) 0 (0.0) 2 (6.9)
(14.3) 0 (0.0) 5 (14.3)
(0.0) 0 (0.0) 1 (33.3)
(21.9) 3 (9.4) 3 (9.4)
¼ 0.1129 P ¼ 0.0303 P ¼ 0.4919
(13.5) 1 (1.9) 2 (3.8)
(10.0) 1 (10.0) 2 (20.0)
(14.8) 0 (0.0) 5 (18.5)
(20.0) 1 (10.0) 2 (20.0)
¼ 0.6920 P ¼ 0.2931 P ¼ 0.0225
(8.1) 2 (3.2) 4 (6.5)
(24.3) 1 (2.7) 7 (18.9)
¼ 0.0254 P ¼ 0.8838 P ¼ 0.0574
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Figure 3 Relationship between expression of the molecular markers and clinical stage in patients with NSCLC. In SP-A
and SP-C, the number of mRNA positive patients correlated significantly with the advance of stage (P ¼ 0.0242 and
0.0275, respectively), whereas it did not in CC10 and CEA (P ¼ 0.4499 and 0.0911, respectively). P value by
Mann–Whitney U test.
22
65
1 64
1
33 patients with positive expression 
of  SP-AmRNA
14 patients with positive 
expression 
of  SP-CmRNA
11 patients with positive 
expression 
of CEAmRNA
Figure 4 Partial overlap of positive results of expression
of SP-A, SP-C and CEA mRNA in patients with NSCLC.
O. Yamamoto et al.1170positive rates of CC10 and CEA mRNAs were not
significantly different (P ¼ 0.8838 and 0.0574,
respectively).
Next, the patients belonging to each stage were
divided into two groups based on the positivity of
mRNA. The deviations in numbers of positive/
negative cases in these two groups were then
analyzed by a non-parametric method using Man-
n–Whitney U test (Fig. 3). The distributions of both
SP-A and SP-C mRNA-positive patients (P ¼ 0.0242
and 0.0275, respectively), deviated significantly in
clinically progressed stages, whereas those in CC10
and CEA (P ¼ 0.4499 and 0.0911, respectively) did
not exhibit significant deviation.Comparison of the positive rate of mRNA for
each molecular marker in each clinical stage
of NSCLC
In the NSCLC cases, the positive rate (33.3%) for SP-
A mRNA was significantly higher than for SP-C
mRNA(14.1%) and CEA mRNA (11.1%) (P ¼ 0.0015
and 0.0002, respectively; w2 test), as described
above. Of particular note, the positivity of SP-A
mRNA was three times higher than that of CEA
mRNA. When compared at each clinical stage, the
patients in stage I also showed a significantly higher
positive rate (22.3%) for SP-A mRNA than that
(5.7%) for CEA mRNA (P ¼ 0.0404, w2 test). The
patients in stage IV also exhibited a significant
difference (P ¼ 0.0130, w2 test) between the
positive rates of SP-A mRNA (45.9%) and CEA mRNA
(18.9%). We next analyzed only the patients with-
out metastasis (stages I–III). The positive rate
(25.8%) for SP-A mRNA was significantly
(P ¼ 0.0034 and 0.0084, respectively; w2 test)higher than it was for SP-C mRNA (8.1%) and CEA
mRNA (6.5%).
Analysis of positive rate of mRNA expression
by the combination of each molecular
marker
In the 99 patients with NSCLC, the number of
positive patients for each marker and the positive
number in terms of the combinations of those
markers are shown in Fig. 4. Since CC10 mRNA was
detected in only three samples, it was excluded
from this analysis. When the expression of SP-A
mRNA alone was analyzed, the rate of detection
was 33.3% (n ¼ 33). By the addition of both SP-C
and CEA to the SP-A, the detection rate was
improved from 33.3% to 45.5% (n ¼ 45). A similar
result was obtained when the patients were divided
into two groups with and without metastasis
(n ¼ 37 and 62, respectively). Thus, by the combi-
nation of SP-A, SP-C and CEA, the detection rate
increased from 45.9% (n ¼ 17) to 59.5% (n ¼ 22) in
patients with metastasis, and from 25.8% (n ¼ 16)
to 37.1% (n ¼ 23) in patients without metastasis.
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Detection of SP-A and SP-D mRNA in circulation 1171The mRNA expressions in preoperative and
postoperative peripheral blood samples from
patients with NSCLC
Thirty-six of the 99 NSCLC patients underwent
curative surgical operation. Eight (7 with adeno-
carcinomas, 1 with squamous cell carcinoma) of the
36 patients, who showed positive mRNA expression
in at least one of three markers prior to their
operation, were examined for mRNA expression
again after the operation. The clinical status of all
the patients thus subjected was stage I. Five
positive reactions for SP-A mRNA, two for SP-C
mRNA and one for CEA mRNA detected prior to
operation had completely disappeared after opera-
tion.
Relation between serum protein
concentration and mRNA positivity
We next examined whether expressions of mRNA
for SP-A and CEA are associated with their protein
concentrations (Fig. 5). The difference in serum
levels of SP-A was not significant between SP-A
mRNA-positive and -negative groups. There was
also no significant difference between CEA protein
and its mRNADiscussion
In determining the prognosis of patients suffering
from primary lung carcinomas, the most important
question is whether or not the lesion is metastatic
to other organs. The formation of metastasis is
completed by a multi-step process, which consists
of invasion of a tumor cell to a blood vessel,
movement into circulating blood, the implantationpositive
SP-A mRNA
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Figure 5 Relationship between the expressions of mRNA and
values were 43.8 ng/ml for SP-A40 and 5.9 ng/ml for CEA. No
found in between mRNA positive group and negative group, r
test).to a secondary organ, and proliferation.14–16 Clin-
icians can only detect the existence of metastasis
when the process has finally proceeded to the last
step; namely, proliferation. If cancer cells could be
detected in peripheral blood, clinicians would be
able to identify patients at high risk of metastasis.
Recently, Tanaka and colleagues developed a mouse
model that human NSCLC produce a neutrophil
elastase-like molecule, and concluded that circu-
lating tumor cells might play a central role in the
metastatic process.17 In the present study, we
attempted to investigate whether the novel meth-
od of RT-PCR for mRNA of SP-A, SP-C, and CC10 is a
useful tool for detecting lung carcinoma cells in
circulating peripheral blood.
Four subtypes of SP (SP-A, SP-B, SP-C and SP-D),
with different structural and functional qualities,
have so far been identified. SP-A and SP-D belong to
a collectin family and are regulators of host
defense within the lungs.18,19 SP-A, SP-B and SP-D
are synthesized by alveolar type II cells and Clara
cells, while SP-C is produced only by alveolar type II
cells in normal lungs.20 Previous reports have shown
that mRNAs of SP-A and SP-C were detected in
lymphnodes21 and pleural effusion22 from patients
with lung adenocarcinoma. These evidences made
us consider that the mRNAs are potential molecular
markers to detect carcinoma cells in the peripheral
blood. CC10 is abundantly expressed in Clara cells,
and is also considered as a specific molecular
marker of the lung. CEA is a molecular marker
whose expression is widely seen in neoplastic
diseases. In this study, we performed RT-PCR
analysis of mRNA of these markers in the peripheral
blood, and compared their specificities and positive
rates of expressions.
To distinguish primary lung carcinoma from
secondary lung carcinoma is critically important,
but often difficult. Our investigation showed that0
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serum protein levels. (a) SP-A; (b) CEA. The upper normal
significant difference in serum level of SP-A or CEA was
espectively. (P ¼ 0.6404 and 0.3342, by Mann–Whitney U
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O. Yamamoto et al.1172SP-A and SP-C mRNA were detected in only NSCLC,
suggesting they are highly specific to primary lung
carcinomas, especially NSCLC. On the other hand,
CEA may be not specific to lung carcinomas. CC10
was not useful as a marker because of a very low
positive mRNA expression rate. Thus, RT-PCR for
SP-A and SP-C are thought to be useful tools to
distinguish primary lung carcinoma from secondary
lung carcinoma.
In this study, no patient with SCLC showed
positive for mRNAs of SP-A and SP-D. The high
specificity of the mRNAs in NSCLC is compatible for
the results shown in previous studies of immuno-
histochemistry9,23 and cell lines.10 The difference
between NSCLC and SCLC may be caused by the
difference in their derivation.24,25 When considered
within NSCLC, there was no significant difference in
the positive rate of SP-A mRNA between adenocar-
cinoma and squamous cell carcinoma. Previous
study also showed that squamous cell carcinoma
also expressed SP-A in an immunohistochemical
evaluation.26
As shown in Fig. 1 in the results section, the RT-
PCR system we used may be able to detect a few
cancer cells from huge gathering of mononuclear
cells with extreme accuracy. When the molecular
markers were compared together in NSCLC pa-
tients, SP-A mRNA appeared to be the best marker
for detecting NSCLC cells in peripheral blood. It
was noteworthy that mRNA was detected even in
patients showing no critical metastasis. The ex-
pressions of mRNA for SP-A, SP-C and CEA dis-
appeared after curative resection of lung
carcinomas at stage I. These results demonstrate
that the movement of cancer cells into the
circulating blood is initiated earlier than we had
believed.
Approximately half of the patients with metas-
tasis were SP-A mRNA positive. Thus, there is a
limit to the usefulness of RT-PCR assay using a
single molecular marker. To overcome this limit, we
examined whether the positive rate is increased by
the combination of SP-A, SP-C and CEA. Analysis of
these three mRNA markers together for stage IV
patients improved the positive rate from 45.9% to
59.5%. A similar result was obtained from the
analysis of all the 99 NSCLC patients; the positive
rate increased from 33.3% to 45.5%. Therefore, the
combination assay would seem to be a useful tool in
the diagnosis of occult metastasis of NSCLC.
It has been reported that the expression of CC10
decreases with increasing carcinogenesis, and that
the transfection of CC10 suppressed the invasion of
carcinomas.27 In immunohistochemical studies of
the primary tumor lesions of lung adenocarcino-
mas, the positive rates for CC10 are only10–20%.9,28 Therefore, it is probable that lung
adenocarcinoma cells existing in peripheral blood
and metastatic lesions would show a lower positive
rate of CC10 expression than those in primary
lesions. This possibility is supported by our study’s
findings on CC10 and it indicates that RT-PCR for
CC10 is not adequate to detect occult lung
carcinoma in blood.
The positive rate (11.1%) for CEA mRNA in this
study was inconsistent with those (60% and 28.6%)
in previous reports.3,29 CEA belongs to the CEA-
family, which consists of five members and pos-
sesses a 70–90% homology of primary structure.30,31
Therefore, the difference in detection rates of CEA
mRNA may be due to the different primer designs.
The primer we chose was previously reported to
provide an extremely high specificity for CEA and
not to amplify other CEA families.32,33
The correlations between serum protein levels
and expressions of mRNA were analyzed in SP-A and
CEA. Guadagni and colleagues34 have reported that
no significant correlation between serum protein
levels and expressions of CEA mRNA was found in
peripheral blood samples from colorectal patients.
Likewise, in our result there was no correlation
between serum protein levels and mRNA expres-
sions in either SP-A or CEA. Thus, serum protein
levels and their mRNA expressions would appear to
be independent factors.
This study indicates that mRNAs of SP-A and SP-C
in peripheral blood may be molecular markers with
a high specificity to NSCLC since they were
expressed, essentially, exclusively in NSCLC.
Furthermore, the positive rate for mRNA of SP-A
and SP-C were dependent on the clinical stage of
carcinoma and the existence of distant metastasis.
It is therefore suggested that the detection of SP-A
and SP-C mRNAs would give clinicians critical
information concerning the progression of clinical
states and distant metastasis.Acknowledgement
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